<DOC>
	<DOCNO>NCT00064077</DOCNO>
	<brief_summary>This randomized phase III trial study four combination chemotherapy regimens use cisplatin compare well work treat woman stage IVB , recurrent , persistent cancer cervix . Drugs use chemotherapy cisplatin , paclitaxel , vinorelbine , gemcitabine , topotecan , use different way stop tumor cell divide stop grow die . It yet know combination chemotherapy regimen contain cisplatin effective treat cervical cancer .</brief_summary>
	<brief_title>Comparison Four Combination Chemotherapy Regimens Using Cisplatin Treating Patients With Stage IVB , Recurrent , Persistent Cancer Cervix</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare survival response patient stage IVB , recurrent , persistent carcinoma cervix treat paclitaxel cisplatin v vinorelbine cisplatin vs gemcitabine cisplatin vs topotecan cisplatin . II . Compare toxic effect regimens patient . III . Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 4 treatment arm . ARM I : Patients receive paclitaxel IV 24 hour day 1 cisplatin IV 1-4 hour day 2 . ARM II : Patients receive vinorelbine IV 6-10 minute day 1 8 cisplatin IV 1-4 hour day 1 . ARM III : Patients receive gemcitabine IV 30-60 minute day 1 8 cisplatin arm II . ARM IV : Patients receive topotecan IV 30 minute day 1-3 cisplatin arm II . In arm , treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Quality life assess baseline , course 2 5 , 9 month study entry . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Histologically confirm squamous cell carcinoma , adenosquamous carcinoma , adenocarcinoma cervix Stage IVB , recurrent , persistent disease Not amenable curative surgery and/or radiotherapy At least 1 unidimensionally measurable lesion At least 20 mm palpation , plain xray , CT scan , MRI OR least 10 mm spiral CT scan Biopsy confirmation require lesion less 30 mm Target lesion must outside previously irradiated field No craniospinal metastasis Performance status GOG 01 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 time normal Alkaline phosphatase great 3 time normal AST great 3 time normal Creatinine ≤ 1.2 mg/dL Creatinine &gt; 1.2 mg/dL &lt; 1.5 mg/dL AND creatinine clearance ≥ 50 mL/min No bilateral hydronephrosis alleviate ureteral stent percutaneous drainage Not pregnant nursing Fertile patient must use effective contraception No prior concurrent malignancy within past 5 year except nonmelanoma skin cancer No prior malignancy whose treatment contraindicate current study therapy No concurrent clinically significant infection No concurrent cytokine At least 6 week since prior chemoradiotherapy recover No prior chemotherapy ( except concurrently administer radiotherapy ) At least 3 week since prior radiotherapy recover Recovered prior surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>